Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2016 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The key is whether management's forward account is substantially about the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' trajectories. Let's analyze the transcript. The company is Bristol-Myers Squibb, a pharmaceutical company. The call discusses their products, especially Opdivo, Yervoy, Eliquis, etc. The "counterparties" in this context could be payers, healthcare systems, or perhaps partners like Pfizer for Eliquis. But the question is about management narrating what counterparties are doing and scaling. Looking at the transcript, management discusses their own commercial execution, their own R&D programs, their own pipeline. They talk about market dynamics, competition, and their own strategies. They mention international business, reimbursement negotiations, and uptake curves. However, they do not seem to be narrating the growth of specific counterparties as the driver of their own business. They talk about their own sales, their own market share, their own launches. They mention "we have assumed the approval of KEYNOTE-021" which is a competitor's product, but that's about competition, not about a counterparty they supply. The question specifically asks about counterparties that the company already supplies or serves, such as customers, partners, licensees, distributors, payers, operators, or programs. In the pharma context, perhaps they could be talking about payers like insurance companies or government programs, but they don't describe those entities' own expansion. They talk about reimbursement decisions, but that's more about access, not about the counterparty scaling. They also mention their partnership with Pfizer for Eliquis, but they don't narrate Pfizer's own growth as the driver; they talk about Eliquis sales and the profit share. Thus, management's forward account is primarily about their own actions, their own pipeline, their own commercial execution, and market conditions. They do not describe specific counterparties' own trajectories as the reason for their coming volume.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.